^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Small Lymphocytic Lymphoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/03/2020
    Excerpt:
    Nivolumab and pembrolizumab ± ibrutinib are included as options with a category 2B recommendation for patients unable to receive chemoimmunotherapy, patients with del (17p) or TP53 mutation, or those with chemoimmunotherapy-refractory disease.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Excerpt:
    ...TP53 mutations, SF3B1 mutations, or NOTCH1 mutation....
    Trial ID:
    NCT03204188